6:33 PM
 | 
Oct 15, 2012
 |  BC Extra  |  Company News

Delcath falls on longer-than-expected NDA review

Delcath Systems Inc. (NASDAQ:DCTH) fell $0.39 (19%) to $1.70 on Monday after FDA did not grant the company's request for Priority Review of an NDA...

Read the full 108 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >